WAUKEGAN, Ill.--(BUSINESS WIRE)--June 8, 2006--NeoPharm (Nasdaq:NEOL - News) today announced that it has received notification that the Company's cintredekin besudotox (IL13-PE38QQR) Pivotal Phase III PRECISE trial for the treatment of Glioblastoma Multiforme (GBM), the most aggressive form of brain cancer, has reached the criterion for the interim efficacy statistical analysis (160 deaths). As a result, the PRECISE trial's independent Data Monitoring Committee (DMC) will assess the study data to date, conduct an interim efficacy analysis, and thereafter provide its recommendation to the Company. The Company currently expects to receive the DMC's recommendation within 10-14 business days.
